Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
...
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study
- Conditions
- Interventions
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 126
- Registration Number
- NCT01700322
- Locations
- 🇩🇪
2 Medical Clinic, Mainz, Germany
Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Pusan National University Yangsan Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01660373
- Locations
- 🇰🇷
Pusan National University Yangsan Hospital, Yangsan, Kyeongsangnamdo, Korea, Republic of
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel
- Conditions
- Interventions
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 500
- Registration Number
- NCT01643031
- Locations
- 🇮🇱
Rabin Medical Center, Petah-Tikva, Israel
Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 56
- Registration Number
- NCT01642966
- Locations
- 🇬🇷
Cardiology Department Patras University Hospital, Patras, Achaia, Greece
Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study
- Conditions
- Interventions
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 30
- Registration Number
- NCT01642940
- Locations
- 🇬🇷
Cardiology Department Patras University Hospital, Patras, Achaia, Greece
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 343
- Registration Number
- NCT01603082
- Locations
- 🇺🇸
Research Site, Richmond, Virginia, United States
Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT01595854
- Locations
- 🇩🇪
1160.141.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 83
- Registration Number
- NCT01575795
- Locations
- 🇬🇷
Cardiology Department Patras University Hospital, Rio, Achaia, Greece
High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients
- Conditions
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 81
- Registration Number
- NCT01543932
- Locations
- 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy
PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Gennaro Sardella
- Target Recruit Count
- 50
- Registration Number
- NCT01531114
- Locations
- 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.